Open Access Target Validation Is a More Efficient Way to Accelerate Drug Discovery
Open Access
- 4 June 2015
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLoS Biology
- Vol. 13 (6), e1002164
- https://doi.org/10.1371/journal.pbio.1002164
Abstract
There is a scarcity of novel treatments to address many unmet medical needs. Industry and academia are finally coming to terms with the fact that the prevalent models and incentives for innovation in early stage drug discovery are failing to promote progress quickly enough. Here we will examine how an open model of precompetitive public–private research partnership is enabling efficient derisking and acceleration in the early stages of drug discovery, whilst also widening the range of communities participating in the process, such as patient and disease foundations.This publication has 43 references indexed in Scilit:
- Bromodomain Proteins in HIV InfectionViruses, 2013
- A New Class of Small Molecule Inhibitor of BMP SignalingPLOS ONE, 2013
- BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-MycCell, 2011
- Bromodomains as therapeutic targetsExpert Reviews in Molecular Medicine, 2011
- Short Hairpin RNA Screen Reveals Bromodomain Proteins as Novel Targets in Acute Myeloid LeukemiaCancer Cell, 2011
- The case for open‐access chemical biologyEMBO Reports, 2009
- The scientific impact of the Structural Genomics Consortium: a protein family and ligand-centered approach to medically-relevant human proteinsJournal of Structural and Functional Genomics, 2007
- Epigenetics in human disease and prospects for epigenetic therapyNature, 2004
- The International HapMap ProjectNature, 2003
- A map of human genome sequence variation containing 1.42 million single nucleotide polymorphismsNature, 2001